Tilson: AIG Is No V...
Health Care: Drugs
Onyx Pharmaceuticals Inc. (ONXX: NASDAQ)
$95.65 0.30 | 0.31%
05/17/13 - 04:00 PM ET
686.97K / 1.27M
Vol / Avg. Vol:96.26 / 95.35
Open / Prev. Close:94.39 - 96.49
Today's Range:41.26 - 101.57
52 Wk Range:26.24%
Performance YTD:TheStreet Rating:
Portfolios with ONXX
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- Contributor4 Drug Stocks Facing FDA Ap...
- ContributorHot Biotech Stocks Traded b...
- ContributorStocks Rising On Unusual Vo...
- Userplayers
- ContributorBreakout Stocks Of The Week...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Rising On Unusual Vo...
Latest ONXX Headlines from TheStreet
- Onyx Reaches New 52-Week High (ONXX) 04.10.13 | 10:04 am
- Market Takes Aim at Historic Highs Once Again
04.10.13 | 09:04 am - Cramer's Top Stock Picks: QQQ IMGN SGEN ONXX 04.05.13 | 06:04 am
- Onyx Pharmaceuticals Inc. (ONXX): Drugs' Highlighted Dud Of The Day 04.04.13 | 05:04 pm
- 8 Stocks Surging on Big Volume 04.01.13 | 03:04 pm
- Analysts' Actions: INTC ONXX VRSN Z RHAT 03.28.13 | 09:03 am
- Onyx Pharmaceuticals Inc. (ONXX): Today's Highlighted Performer In Drugs 03.25.13 | 05:03 pm
- 8 Stocks With Buy Ratings From Deutsche Bank And UBS 03.14.13 | 01:03 pm
- Onyx Rises On Unusually High Volume (ONXX) 03.07.13 | 04:03 pm
- The Next Big Thing In Biotech: Onyx 03.07.13 | 01:03 pm
Press Releases for ONXX
- Bayer's Stivarga® (regorafenib) Tablets Approved In Japan - PR Newswire 03.25.13 | 05:03 pm
- Bayer's Stivarga® (regorafenib) Tablets Approved By U.S. FDA For Treatment Of Patients With Locally Advanced, Unresectable Or Metastatic GIST - PR Newswire 02.25.13 | 04:02 pm
- Onyx Pharmaceuticals Launches Make Your Mark At The Multiple Myeloma Experience To Champion Progress In Multiple Myeloma Research And Treatment - PR Newswire 12.06.12 | 04:12 pm
- Onyx Pharmaceuticals To Present At Upcoming Investor Conferences - PR Newswire 09.04.12 | 04:09 pm
- Bayer Submits New Drug Application For Regorafenib For The Treatment Of Gastrointestinal Stromal Tumors (GIST) - PR Newswire 08.30.12 | 10:08 am
- Onyx Pharmaceuticals Announces Kyprolis⢠Study Published In The Medical Journal Blood - PR Newswire 07.25.12 | 09:07 am
- Onyx Pharmaceuticals To Report Second Quarter 2012 Financial Results After Market On August 1, 2012 - PR Newswire 07.23.12 | 04:07 pm
- Addition Of Tarceva® (erlotinib) To Nexavar® (sorafenib) Did Not Provide Additional Benefit To Patients With Unresectable Liver Cancer Versus Nexavar Alone In Phase 3 Trial - PR Newswire 07.23.12 | 02:07 am
- Onyx Pharmaceuticals Receives FDA Accelerated Approval Of Kyprolis⢠(carfilzomib) For Injection - PR Newswire 07.20.12 | 12:07 pm
- Onyx Pharmaceuticals Names John E. Osborn Senior Vice President, Global Corporate Affairs - PR Newswire 07.09.12 | 08:07 am
Partner Headlines for ONXX
- Deutsche Bank Reiterates Buy on Onyx Pharmaceuticals on Updated Guidelines - Benzinga 03.11.13 | 01:03 pm
- Four Biotech Stocks On The Clock - Seeking Alpha 02.19.13 | 09:02 am
- Onyx Pharmaceuticals (ONXX) - Bull of the Day - Zacks 12.05.12 | 01:12 am
- Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX) - Benzinga 11.12.12 | 01:11 pm
- Celgene Earnings Beat Views; Guidance Raised A Bit - Investor's Business Daily 10.25.12 | 04:10 pm
- Onyx Enrolls FOCUS Patients - Analyst Blog - Zacks 10.22.12 | 05:10 pm
- CHMP Positive on Novartis' Votubia - Analyst Blog - NASDAQ 09.24.12 | 06:09 pm
- Bulls stay hooked with Onyx uptrend - NASDAQ 09.20.12 | 03:09 pm
- FDA Panel to Review Celgene Drug - Analyst Blog - NASDAQ 09.20.12 | 01:09 pm
- FDA Panel to Review Celgene Drug - Analyst Blog - Zacks 09.20.12 | 10:09 am
